Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome

Valeriana Cesarini, Maurizio Martini, Lucia Ricci Vitiani, Giovanni Luca Gravina, Silvia Di Agostino, Grazia E. Graziani, Quintino Giorgio D'Alessandris, Roberto Pallini, Luigi M. Larocca, Pellegrino Rossi, Emmanuele A. Jannini, Susanna Dolci

Research output: Contribution to journalArticle

Abstract

Expression of type 5 phosphodiesterase (PDE5), a cGMP-specific hydrolytic enzyme, is frequently altered in human cancer, but its specific role in tumorigenesis remains controversial. Herein, by analyzing a cohort of 69 patients affected by glioblastoma multiforme (GBM) who underwent chemo- and radiotherapy after surgical resection of the tumor, we found that PDE5 was strongly expressed in cancer cells in about 50% of the patients. Retrospective analysis indicated that high PDE5 expression in GBM cells significantly correlated with longer overall survival of patients. Furthermore, silencing of endogenous PDE5 by short hairpin lentiviral transduction (sh-PDE5) in the T98G GBM cell line induced activation of an invasive phenotype. Similarly, pharmacological inhibition of PDE5 activity strongly enhanced cell motility and invasiveness in T98G cells. This invasive phenotype was accompanied by increased secretion of metallo-proteinase 2 (MMP-2) and activation of protein kinase G (PKG). Moreover, PDE5 silencing markedly enhanced DNA damage repair and cell survival following irradiation. The enhanced radio-resistance of sh-PDE5 GBM cells was mediated by an increase of poly(ADP-ribosyl)ation (PARylation) of cellular proteins and could be counteracted by poly(ADP-ribose) polymerase (PARP) inhibitors. Conversely, PDE5 overexpression in PDE5-negative U87G cells significantly reduced MMP-2 secretion, inhibited their invasive potential and interfered with DNA damage repair and cell survival following irradiation. These studies identify PDE5 as a favorable prognostic marker for GBM, which negatively affects cell invasiveness and survival to ionizing radiation. Moreover, our work highlights the therapeutic potential of targeting PKG and/or PARP activity in this currently incurable subset of brain cancers.

Original languageEnglish
Pages (from-to)13223-13239
Number of pages17
JournalOncotarget
Volume8
Issue number8
DOIs
Publication statusPublished - Jan 1 2017

    Fingerprint

Keywords

  • Glioblastoma
  • MMP2
  • MYPT
  • PARP
  • PDE5

ASJC Scopus subject areas

  • Oncology

Cite this

Cesarini, V., Martini, M., Vitiani, L. R., Gravina, G. L., Di Agostino, S., Graziani, G. E., D'Alessandris, Q. G., Pallini, R., Larocca, L. M., Rossi, P., Jannini, E. A., & Dolci, S. (2017). Type 5 phosphodiesterase regulates glioblastoma multiforme aggressiveness and clinical outcome. Oncotarget, 8(8), 13223-13239. https://doi.org/10.18632/oncotarget.14656